CY1121233T1 - Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα καtα του υποδοχεα iντερλευκinης-4(ιl-4r) - Google Patents
Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα καtα του υποδοχεα iντερλευκinης-4(ιl-4r)Info
- Publication number
- CY1121233T1 CY1121233T1 CY20181100959T CY181100959T CY1121233T1 CY 1121233 T1 CY1121233 T1 CY 1121233T1 CY 20181100959 T CY20181100959 T CY 20181100959T CY 181100959 T CY181100959 T CY 181100959T CY 1121233 T1 CY1121233 T1 CY 1121233T1
- Authority
- CY
- Cyprus
- Prior art keywords
- receptor
- interleukin
- preparations containing
- containing antibodies
- antibody
- Prior art date
Links
- 102000010787 Interleukin-4 Receptors Human genes 0.000 title 2
- 108010038486 Interleukin-4 Receptors Proteins 0.000 title 2
- 238000002360 preparation method Methods 0.000 title 1
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 102000054663 human IL4R Human genes 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31511—Piston or piston-rod constructions, e.g. connection of piston with piston-rod
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/2006—Having specific accessories
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/19—Constructional features of carpules, syringes or blisters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Η παρούσα εφεύρεση παρέχει φαρμακευτικά σκευάσματα που περιλαμβάνουν ένα ανθρώπινο αντίσωμα το οποίο δεσμεύεται ειδικά με τον υποδοχέα της ανθρώπινης ιντερλευκίνης-4 (hlL-4R). Τα σκευάσματα μπορεί να περιέχουν, επιπλέον ενός αντισώματος αντι-hlL-4R, τουλάχιστον ένα αμινοξύ, τουλάχιστον ένα σάκχαρο ή τουλάχιστον ένα μη ιοντικό επιφανειοδραστικό. Τα φαρμακευτικά σκευάσματα της παρούσας εφεύρεσης επιδεικνύουν σημαντικό βαθμό σταθερότητας του αντισώματος μετά την αποθήκευση για αρκετούς μήνες.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39028310P | 2010-10-06 | 2010-10-06 | |
PCT/US2011/054856 WO2012047954A1 (en) | 2010-10-06 | 2011-10-05 | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
US13/253,103 US8945559B2 (en) | 2010-10-06 | 2011-10-05 | Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121233T1 true CY1121233T1 (el) | 2020-05-29 |
Family
ID=44802412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181100959T CY1121233T1 (el) | 2010-10-06 | 2018-09-18 | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα καtα του υποδοχεα iντερλευκinης-4(ιl-4r) |
Country Status (20)
Country | Link |
---|---|
US (6) | US8945559B2 (el) |
EP (3) | EP3733711A1 (el) |
JP (3) | JP5918246B2 (el) |
KR (1) | KR101867279B1 (el) |
CN (2) | CN106267189B (el) |
AU (1) | AU2011312191B2 (el) |
BR (1) | BR112013008366B1 (el) |
CA (1) | CA2813587C (el) |
CL (1) | CL2013000912A1 (el) |
CY (1) | CY1121233T1 (el) |
EA (2) | EA034617B1 (el) |
IL (3) | IL283424B2 (el) |
MX (4) | MX344294B (el) |
MY (1) | MY158130A (el) |
NZ (1) | NZ609557A (el) |
PL (2) | PL2624865T3 (el) |
PT (1) | PT2624865T (el) |
SG (1) | SG189220A1 (el) |
WO (1) | WO2012047954A1 (el) |
ZA (1) | ZA201302460B (el) |
Families Citing this family (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
NZ609557A (en) | 2010-10-06 | 2014-12-24 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
WO2012101253A1 (en) | 2011-01-28 | 2012-08-02 | Sanofi | Pharmaceutical compositions comprising human antibodies to pcsk9 |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
EP3536712B1 (en) | 2011-09-16 | 2023-05-31 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9) |
EP2790681B9 (en) | 2011-11-18 | 2023-07-26 | Regeneron Pharmaceuticals, Inc. | Method of manufacturing an extended release pharmaceutical formulation comprising polymer coated protein microparticles using spray-drying |
SG11201403792TA (en) | 2012-01-23 | 2014-10-30 | Regeneron Pharma | Stabilized formulations containing anti-ang2 antibodies |
US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
AR092325A1 (es) * | 2012-05-31 | 2015-04-15 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit |
ES2900342T3 (es) | 2012-08-21 | 2022-03-16 | Sanofi Biotechnology | Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R |
US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
WO2014039461A1 (en) | 2012-09-07 | 2014-03-13 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
KR20150070384A (ko) * | 2012-10-25 | 2015-06-24 | 메디뮨 엘엘씨 | 안정한 저점도 항체 제제 |
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
WO2014197752A1 (en) | 2013-06-07 | 2014-12-11 | Regeneron Pharmaceuticals, Inc. | Methods fo inhibting atherosclerosis by administering an inhibitor of pcsk9 |
JP6463351B2 (ja) * | 2013-06-21 | 2019-01-30 | サノフィ・バイオテクノロジー | Il−4rアンタゴニストの投与により鼻茸を処置する方法 |
TWI682781B (zh) * | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
EP3564671B1 (en) | 2013-08-23 | 2021-09-29 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) |
KR20160081978A (ko) | 2013-11-12 | 2016-07-08 | 사노피 바이오테크놀로지 | Pcsk9 억제제의 사용을 위한 투약 요법 |
KR20220029765A (ko) | 2014-02-21 | 2022-03-08 | 사노피 바이오테크놀로지 | Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법 |
CN106062000B (zh) | 2014-02-28 | 2021-05-28 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗皮肤感染的方法 |
PL3169353T3 (pl) | 2014-07-16 | 2020-06-01 | Sanofi Biotechnology | SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH) |
RU2017107847A (ru) * | 2014-09-03 | 2018-10-03 | Медиммун Лимитед | Стабильный состав на основе антитела к il-4r-альфа |
CN107206073A (zh) * | 2014-11-14 | 2017-09-26 | 赛诺菲生物技术公司 | 通过施用il‑4r拮抗剂用于治疗伴随鼻息肉的慢性鼻窦炎的方法 |
TWI797060B (zh) | 2015-08-04 | 2023-04-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
CA2995645A1 (en) | 2015-08-18 | 2017-02-23 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
CA3014202A1 (en) | 2016-02-19 | 2017-08-24 | Regeneron Pharmaceuticals, Inc. | Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist |
EP3448391A4 (en) | 2016-04-27 | 2019-12-18 | AbbVie Inc. | METHODS OF TREATING DISEASES IN WHICH IL-13 ACTIVITY IS HARMFUL WITH ANTI-IL-13 ANTIBODIES |
CN107474134B (zh) | 2016-06-08 | 2021-07-27 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
MA46098A (fr) | 2016-09-01 | 2019-07-10 | Regeneron Pharma | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r |
MX2019003235A (es) | 2016-09-22 | 2019-07-08 | Regeneron Pharma | Metodos para tratar dermatitis atopica severa administrando un inhibidor de receptor de isoleucina-4. |
US10485844B2 (en) | 2016-09-22 | 2019-11-26 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor |
BR112019010331A2 (pt) | 2016-11-29 | 2019-10-22 | Regeneron Pharma | composição farmacêutica para evitar a dependência de opioides |
TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
WO2018118713A1 (en) | 2016-12-22 | 2018-06-28 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
EP3576790A4 (en) | 2017-02-01 | 2020-12-23 | Yale University | TREATMENT OF DIURETIC RESISTANCE |
JP6172880B1 (ja) * | 2017-02-01 | 2017-08-02 | 協和発酵キリン株式会社 | ダルベポエチンを含む液体医薬組成物 |
CA3060581A1 (en) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
KR20210084695A (ko) | 2017-07-06 | 2021-07-07 | 리제너론 파마슈티칼스 인코포레이티드 | 당단백질을 만들기 위한 세포 배양 과정 |
WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
CA3079946A1 (en) | 2017-10-30 | 2019-05-09 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
EP3727629A1 (en) | 2017-12-22 | 2020-10-28 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing drug product impurities |
BR112020013519A2 (pt) | 2018-01-05 | 2020-12-01 | Corvidia Therapeutics, Inc | método para tratamento de uma inflamação. |
CN111655722A (zh) | 2018-01-31 | 2020-09-11 | 瑞泽恩制药公司 | 用于表征药物产品杂质的系统和方法 |
TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
BR112020013426A2 (pt) | 2018-02-28 | 2020-12-01 | Regeneron Pharmaceuticals, Inc. | métodos para identificação de um vírus em uma amostra e para detecção de ácidos nucleicos virais em uma amostra de cultura de células |
CN111868085A (zh) | 2018-03-19 | 2020-10-30 | 瑞泽恩制药公司 | 微芯片毛细管电泳测定法及试剂 |
TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
EP3793597A1 (en) | 2018-05-13 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r inhibitor |
MX2021001549A (es) | 2018-08-10 | 2021-04-13 | Regeneron Pharma | Una composicion farmaceutica para el tratamiento seguro y efectivo del dolor de rodilla y/o cadera. |
CN112218877A (zh) | 2018-08-27 | 2021-01-12 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
CN112601963A (zh) | 2018-08-30 | 2021-04-02 | 瑞泽恩制药公司 | 用于表征蛋白质复合物的方法 |
US20210324052A1 (en) * | 2018-10-18 | 2021-10-21 | Merck Sharp & Dohme Corp. | Formulations of anti-rsv antibodies and methods of use thereof |
CN113166259A (zh) * | 2018-11-09 | 2021-07-23 | 亚洲大学校产学协力团 | 对人IL-4受体α具有高亲和力的人抗体及其用途 |
US11312778B2 (en) | 2018-11-21 | 2022-04-26 | Brian C. Machler | Method for treating allergic contact dermatitis |
CA3116732A1 (en) | 2019-01-16 | 2020-07-23 | Regeneron Pharmaceuticals, Inc. | Methods for identifying free thiols in proteins |
MA55033A (fr) | 2019-02-18 | 2021-12-29 | Lilly Co Eli | Formulation d'anticorps thérapeutique |
AU2020231343A1 (en) | 2019-03-06 | 2021-10-21 | Regeneron Pharmaceuticals, Inc. | IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer |
CN111686247B (zh) * | 2019-03-13 | 2022-07-29 | 苏州康乃德生物医药有限公司 | 包含人白介素-4受体α的抗体的液体组合物 |
TW202102260A (zh) * | 2019-03-21 | 2021-01-16 | 美商再生元醫藥公司 | 含有抗il-33抗體之穩定調配物 |
AU2020240132A1 (en) | 2019-03-21 | 2021-09-16 | Regeneron Pharmaceuticals, Inc. | Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy |
AU2020266593A1 (en) | 2019-05-01 | 2021-11-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating or preventing asthma by administering an IL-33 antagonist |
EP3969908A1 (en) | 2019-05-13 | 2022-03-23 | Regeneron Pharmaceuticals, Inc. | Improved competitive ligand binding assays |
CA3147436A1 (en) | 2019-07-16 | 2021-01-21 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
SG11202113310UA (en) | 2019-08-05 | 2021-12-30 | Regeneron Pharma | Methods for treating atopic dermatitis by administering an il-4r antagonist |
CA3147068A1 (en) | 2019-08-05 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
MX2022003438A (es) | 2019-09-24 | 2022-04-19 | Regeneron Pharma | Sistemas y metodos para uso y regeneracion de cromatografia. |
KR20220104797A (ko) | 2019-11-25 | 2022-07-26 | 리제너론 파마슈티칼스 인코포레이티드 | 비수성 에멀전을 이용한 지속 방출 제형 |
BR112022011098A2 (pt) | 2019-12-09 | 2022-09-20 | Sanofi Biotechnology | Métodos para tratamento de distúrbios relacionados a il-4/il-13 digitalmente identificados |
EP3992974A1 (en) | 2020-11-02 | 2022-05-04 | Sanofi Biotechnology | Methods for treating digitally-identified il-4/il-13 related disorders |
WO2021133776A1 (en) | 2019-12-23 | 2021-07-01 | Sanofi Biotechnology | Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist |
KR102544013B1 (ko) | 2020-01-21 | 2023-06-19 | 리제너론 파마슈티칼스 인코포레이티드 | 당질화된 단백질의 전기영동을 위한 탈당질화 방법 |
CA3169959A1 (en) * | 2020-02-21 | 2021-08-26 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition containing anti-il-4r antibody and use thereof |
KR20220158821A (ko) | 2020-03-27 | 2022-12-01 | 리제너론 파아마슈티컬스, 인크. | Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법 |
EP4153300A1 (en) | 2020-05-22 | 2023-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
CN113797331A (zh) * | 2020-06-16 | 2021-12-17 | 三生国健药业(上海)股份有限公司 | 一种稳定的抗IL-4Rα单克隆抗体液体制剂 |
WO2022010988A1 (en) * | 2020-07-08 | 2022-01-13 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ctla-4 antibodies |
EP4204578A1 (en) | 2020-08-31 | 2023-07-05 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
JP2023544406A (ja) | 2020-10-05 | 2023-10-23 | サノフィ・バイオテクノロジー | Il-4rアンタゴニストを投与することによって小児対象における喘息を治療するための方法 |
KR20230113280A (ko) | 2020-11-25 | 2023-07-28 | 리제너론 파마슈티칼스 인코포레이티드 | 비수성 멤브레인 유화법을 사용한 지속 방출 제형 |
KR20230121854A (ko) | 2020-12-17 | 2023-08-21 | 리제너론 파아마슈티컬스, 인크. | 단백질-캡슐화 마이크로겔의 제작 |
KR20230130681A (ko) | 2021-01-08 | 2023-09-12 | 리제너론 파아마슈티컬스, 인크. | Il-4r 길항제 투여에 의한 땅콩 알레르기를 치료하는방법 및 땅콩 알레르기원 특이적 면역치료를 강화하는 방법 |
TW202233827A (zh) | 2021-01-20 | 2022-09-01 | 美商再生元醫藥公司 | 改良細胞培養中蛋白質效價的方法 |
AU2022230987A1 (en) | 2021-03-03 | 2023-08-31 | Regeneron Pharmaceuticals, Inc. | Systems and methods for quantifying and modifying protein viscosity |
CA3208011A1 (en) | 2021-03-17 | 2022-09-22 | Sarah Harris | Methods of treating atopic dermatitis with anti il-13 antibodies |
BR112023018665A2 (pt) | 2021-03-26 | 2023-10-03 | Regeneron Pharma | Métodos e sistemas para desenvolvimento de protocolos de mistura |
TW202304507A (zh) * | 2021-04-02 | 2023-02-01 | 美商再生元醫藥公司 | 含有抗muc16x抗cd3雙特異性抗體之穩定調配物 |
EP4348234A1 (en) | 2021-06-01 | 2024-04-10 | Regeneron Pharmaceuticals, Inc. | Micropchip capillary electrophoresis assays and reagents |
KR20240037321A (ko) | 2021-07-26 | 2024-03-21 | 사노피 바이오테크놀로지 | Il-4r 길항제의 투여에 의한 만성 자발성 심마진의 치료 방법 |
IL310962A (en) | 2021-08-23 | 2024-04-01 | Regeneron Pharma | Methods for treating atopic dermatitis by administering an IL-4R antagonist |
WO2023039457A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins |
CA3232463A1 (en) * | 2021-09-20 | 2023-03-23 | Philip Mellors | Methods of controlling antibody heterogeneity |
WO2023059800A2 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
AU2022359898A1 (en) | 2021-10-07 | 2024-03-21 | Regeneron Pharmaceuticals, Inc. | Ph meter calibration and correction |
CA3235380A1 (en) | 2021-10-20 | 2023-04-27 | Elizabeth Laws | Methods for treating prurigo nodularis by administering an il-4r antagonist |
TW202330104A (zh) | 2021-10-26 | 2023-08-01 | 美商再生元醫藥公司 | 用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法 |
WO2023092052A1 (en) | 2021-11-19 | 2023-05-25 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for reducing centralized pain |
US20230220089A1 (en) | 2021-12-30 | 2023-07-13 | Regeneron Pharmaceuticals, Inc. | Methods for attenuating atopic march by administering an il-4/il-13 antagonist |
WO2023177836A1 (en) | 2022-03-18 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
US20240002491A1 (en) | 2022-04-27 | 2024-01-04 | Regeneron Pharmaceuticals, Inc. | Methods for selecting patients for treatment with an ngf antagonist |
WO2023215267A1 (en) * | 2022-05-02 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Anti-interleukin-4 receptor (il-4r) antibody formulations |
WO2024011251A1 (en) | 2022-07-08 | 2024-01-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating eosinophilic esophagitis in pediatric by administering an il-4r antagonist |
WO2024047021A1 (en) | 2022-08-29 | 2024-03-07 | Sanofi | Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
JPH11510170A (ja) * | 1995-07-27 | 1999-09-07 | ジェネンテック インコーポレーテッド | タンパク質の処方 |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
EP0999853B1 (en) * | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
EP3190126A1 (en) | 2000-05-26 | 2017-07-12 | Immunex Corporation | Use of interleukin-4 receptor (il-4r) antibodies and compositions thereof |
ES2644275T3 (es) * | 2000-08-11 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Preparaciones estabilizadas que contienen anticuerpos |
JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
BRPI0403964B8 (pt) | 2003-04-04 | 2021-05-25 | Genentech Inc | formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
WO2006088650A2 (en) | 2005-02-02 | 2006-08-24 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a vegf inhibitor |
LT2586459T (lt) | 2005-03-25 | 2017-09-25 | Regeneron Pharmaceuticals, Inc. | Vegf antagonisto kompozicijos |
ES2776657T3 (es) * | 2005-06-14 | 2020-07-31 | Amgen Inc | Formulaciones de proteínas autotamponantes |
LT2944306T (lt) | 2006-06-16 | 2021-02-25 | Regeneron Pharmaceuticals, Inc. | Vfgf antagonisto kompozicijos, tinkamos įvedimui intravitrealiniu būdu |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
CN101522716B (zh) | 2006-10-02 | 2013-03-20 | 瑞泽恩制药公司 | 抗人il-4受体的高亲和力人抗体 |
WO2009009406A1 (en) * | 2007-07-06 | 2009-01-15 | Smithkline Beecham Corporation | Antibody formulations |
PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
EP2328559B1 (en) * | 2008-09-19 | 2015-01-07 | F. Hoffmann-La Roche AG | Formulation comprising antibody against p-selectin |
WO2010042705A1 (en) * | 2008-10-09 | 2010-04-15 | Medimmune, Llc | Antibody formulation |
EP2403874A1 (en) * | 2009-03-06 | 2012-01-11 | Genentech, Inc. | Antibody formulation |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
US20130126858A1 (en) * | 2010-08-05 | 2013-05-23 | Koninklijke Philips Electronics N.V. | Organic electroluminescent device |
NZ609557A (en) | 2010-10-06 | 2014-12-24 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
US9458240B2 (en) * | 2010-12-10 | 2016-10-04 | Novartis Pharma Ag | Anti-BAFFR antibody formulations |
MX367097B (es) * | 2011-05-02 | 2019-08-05 | Millennium Pharm Inc | FORMULACION PARA ANTICUERPO ANTI-A4ß7. |
WO2013131866A1 (en) * | 2012-03-08 | 2013-09-12 | F. Hoffmann-La Roche Ag | Abeta antibody formulation |
ES2900342T3 (es) | 2012-08-21 | 2022-03-16 | Sanofi Biotechnology | Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R |
WO2014039461A1 (en) | 2012-09-07 | 2014-03-13 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
-
2011
- 2011-10-05 NZ NZ60955711A patent/NZ609557A/en unknown
- 2011-10-05 PL PL11770625T patent/PL2624865T3/pl unknown
- 2011-10-05 US US13/253,103 patent/US8945559B2/en active Active
- 2011-10-05 PT PT11770625T patent/PT2624865T/pt unknown
- 2011-10-05 MX MX2013003795A patent/MX344294B/es active IP Right Grant
- 2011-10-05 EP EP20178438.6A patent/EP3733711A1/en active Pending
- 2011-10-05 EA EA201791328A patent/EA034617B1/ru not_active IP Right Cessation
- 2011-10-05 EP EP11770625.9A patent/EP2624865B1/en active Active
- 2011-10-05 EA EA201390494A patent/EA028945B1/ru unknown
- 2011-10-05 IL IL283424A patent/IL283424B2/en unknown
- 2011-10-05 SG SG2013024401A patent/SG189220A1/en unknown
- 2011-10-05 MY MYPI2013001157A patent/MY158130A/en unknown
- 2011-10-05 PL PL18161288T patent/PL3354280T3/pl unknown
- 2011-10-05 CN CN201610677975.7A patent/CN106267189B/zh active Active
- 2011-10-05 AU AU2011312191A patent/AU2011312191B2/en active Active
- 2011-10-05 EP EP18161288.8A patent/EP3354280B1/en active Active
- 2011-10-05 MX MX2016010501A patent/MX366337B/es unknown
- 2011-10-05 BR BR112013008366-2A patent/BR112013008366B1/pt active IP Right Grant
- 2011-10-05 KR KR1020137011620A patent/KR101867279B1/ko active IP Right Grant
- 2011-10-05 CN CN201180058528.9A patent/CN103501814B/zh active Active
- 2011-10-05 JP JP2013532896A patent/JP5918246B2/ja active Active
- 2011-10-05 CA CA2813587A patent/CA2813587C/en active Active
- 2011-10-05 WO PCT/US2011/054856 patent/WO2012047954A1/en active Application Filing
-
2013
- 2013-04-03 IL IL225548A patent/IL225548B/en active IP Right Grant
- 2013-04-04 MX MX2022014596A patent/MX2022014596A/es unknown
- 2013-04-04 CL CL2013000912A patent/CL2013000912A1/es unknown
- 2013-04-04 MX MX2019008084A patent/MX2019008084A/es unknown
- 2013-04-05 ZA ZA2013/02460A patent/ZA201302460B/en unknown
-
2014
- 2014-12-19 US US14/578,179 patent/US9238692B2/en active Active
-
2015
- 2015-12-09 US US14/963,712 patent/US20160102147A1/en not_active Abandoned
-
2016
- 2016-04-07 JP JP2016077089A patent/JP6231605B2/ja active Active
-
2017
- 2017-02-03 US US15/424,578 patent/US10435473B2/en active Active
- 2017-10-18 JP JP2017201473A patent/JP6396565B2/ja active Active
-
2018
- 2018-09-18 CY CY20181100959T patent/CY1121233T1/el unknown
-
2019
- 2019-08-19 US US16/543,832 patent/US11059896B2/en active Active
-
2020
- 2020-05-25 IL IL274902A patent/IL274902B/en active IP Right Grant
-
2021
- 2021-06-09 US US17/342,949 patent/US11926670B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121233T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα καtα του υποδοχεα iντερλευκinης-4(ιl-4r) | |
CY1123909T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r) | |
CY1122181T1 (el) | Φαρμακοτεχνικη μορφη αντισωματος | |
JO3449B1 (ar) | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب | |
PH12014501628B1 (en) | Stabilized formulations containing anti-ang2 antibodies | |
CY1118702T1 (el) | Συνθεση πεπτιδιων που σχετιζονται με ογκους και σχετικου αντικαρκινικου εμβολιου για τη θεραπεια του γλοιοβλαστωματος (glioblastoma, gbm) και αλλων μορφων καρκινου | |
MY157772A (en) | Antibody formulation | |
MX2014004725A (es) | Formulaciones de etanercept estabilizadas con aminoacidos. | |
EA201390145A1 (ru) | Конъюгаты, частицы, композиции и связанные с ними способы | |
CA2872275C (en) | Stabilized formulations containing anti-dll4 antibodies | |
UY33652A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4(il-ar) | |
MX2021011137A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-il-33. | |
TR200909785A1 (tr) | Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar. | |
TN2012000342A1 (en) | Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies | |
EA202090016A3 (ru) | Стабилизированные композиции, содержащие антитела к рецептору интерлейкина-4 (il-4r) |